Leerink Partners raises Oculis stock price target to $50 from $22

On Thursday, Leerink Partners analysts raised the price target for Oculis Holding AG (NASDAQ: OCS) stock to $50 from $22, while maintaining an Outperform rating. Currently trading at $19.15, the stock has shown strong momentum with a 60% return over the past year. This adjustment follows discussions with physicians and insights from a recent analyst meeting. According to InvestingPro data, analyst targets range from $21.93 to $42.15, suggesting significant upside potential.

The analysts expressed increased optimism about Oculis, particularly due to the company’s developments with privosegtor (OCS-05), a SGK activator. SGKs are known to promote antioxidant enzymes and regulate apoptotic genes, which can help prevent demyelination and neuron death.

The decision to raise the price target reflects positive feedback from the medical community regarding Oculis’ Phase 2 data. The discussions highlighted the potential of privosegtor in addressing neurological conditions.

Oculis Holding AG, listed on the NASDAQ under the ticker OCS, continues to focus on advancing its pipeline, with privosegtor being a key component of its strategy. Leerink Partners’ analysts remain confident in the company’s future prospects.

In other recent news, Oculis Holding AG has completed patient enrollment for its Phase 3 DIAMOND-1 and DIAMOND-2 trials, which are evaluating OCS-01 eye drops as a treatment for diabetic macular edema (DME). These trials have enrolled over 800 patients across 119 global sites, primarily in the U.S., with results expected in the second quarter of 2026. Additionally, Oculis reported financial results for 2024, noting grant income of CHF 0.7 million and a net loss of CHF 85.8 million. The company ended the year with cash and equivalents totaling $109 million, supported by a recent financing round of $93 million. Stifel analysts maintained a Buy rating and a $35 price target on Oculis shares, highlighting the company’s innovative research and development strategies. H.C. Wainwright analyst Yi Chen also kept a Buy rating but revised the price target to $29, reflecting changes in market valuation and projected outstanding shares. Oculis is advancing its pipeline, including the OCS-05/privosegtor, which showed positive results in the Phase 2 ACUITY trial for acute optic neuritis. The company plans further discussions with the FDA for its drug candidates, including a meeting in the second half of 2025 for the OCS-05 program.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.